Phase II brain metastases trial advances after futility analysis
Drug Discovery World
SEPTEMBER 6, 2024
The Phase II NANOBRAINMETS trial of AGuIX has been validated by the Data Safety and Monitoring Board (DSMB) following a futility analysis scheduled after the enrolment and follow-up of 50% of patients in the study. A total of 96 patients have been randomised to date of the 134 scheduled in the study’s protocol.
Let's personalize your content